Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial. (2021). SKIN The Journal of Cutaneous Medicine, 5(1), s18. https://doi.org/10.25251/skin.5.supp.18